Oncology

Overview

Invicro uniquely combines operational excellence with extensive scientific and medical expertise. Our goal is to drive the advancement of translational cancer research, aid in cancer drug development and develop imaging methods and tools that enable precision medicine. We have experience working with a wide range of therapeutics, including small molecules, peptides, antibodies, multi-specific proteins, CAR-T cells, and many more. Preclinically and clinically, Invicro offers a wide variety of oncology biomarker solutions, including:

Central imaging core lab for Phase 0-IV clinical studies
Preclinical/Clinical novel molecular imaging tracers
In vitro, in vivo, and ex vivo techniques in rodents through NHPs
Autoradiography, histology and quantitative immunohistochemistry
Qualitative and quantitative image analytics

Capabilities

Radiochemistry

Invicros radiochemistry team has experience with almost all commercially available radioisotopes used for PET/SPECT imaging and several used in targeted radiotherapy. Our capabilities span from first-in-human clinical studies to GMP implementation of novel radiotracers, including:

Rodent Models

We have experience with multiple rodent models and the flexibility to either produce models in-house or receive them from outside vendors or collaborators. Common models include:

Syngeneic models
Human xenograft tumors in immunocompromised mice
Humanized mouse models
GEMM mouse model

We also work with larger species including canine, porcine, and non-human primates (NHP).

Clinical Core Lab

Invicro has a central imaging core lab, including study design, site set-up and training, development of imaging protocol, expert blinded reads and full 21 CFR Part 11 compliance. We have qualitative and advanced quantitative analysis techniques, including:

Segmentation
Image co-registration
Radiation dosimetry
Mechanistic pharmacokinetic modeling including PBPK modeling
Tracer kinetic modeling
Radiomics
Imaged-based machine learning
Full service independent blind reads or collect and hold capabilities
Response criteria – RANO, Lugano, PCWG, IMWG, RECIST, Cheson, iRECIST, irRECIST, irRC and LYRIC

Invicro also brings experience in PET bio-distribution studies using radiolabeled anti-cancer agents.